Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 26th Preview)
-
Gene-editing for LDL lowering moves through early clinical readouts
Eli Lilly reported early Phase 1 results for its VERVE-102 base-editing program, saying a single infusion reduced LDL cholesterol by as much as 62% and sustained the effect for up to 18 months. Lilly previously acquired the asset through its $1 billion buyout of Verve Therapeutics, after an earlier Verve candidate was stopped over safety concerns. In the open-label single-ascending dose study, Lilly said there were no treatment-related serious adverse events, and dosing translated into LDL reductions comparable to those seen with the PCSK9 antibody class in genetically high-cholesterol populations. The company positioned the therapy as a potential one-time approach for patients who struggle to reach LDL targets on existing lipid-lowering regimens. The program targets PCSK9 by editing DNA to alter PCSK9 gene function, aiming to provide long-lasting LDL lowering from a one-time treatment. Lilly’s disclosure adds another data point as the company expands gene-editing and genetic medicine ambitions following prior acquisitions in the modality.
-
Lilly accelerates infectious-disease dealmaking with three vaccine acquisitions
Eli Lilly announced agreements to acquire three private vaccine developers—Vaccine Co., Curevo, and LimmaTech Biologics—expanding its infectious-disease pipeline through a series of transactions that could total nearly $4 billion. The deals deepen Lilly’s effort to pivot from treating downstream complications to preventing disease at its source. Curevo’s lead candidate is an experimental shingles vaccine using a next-generation synthetic adjuvant; Lilly said it produced a similar immune response to a standard shingles shot in Phase 2 while showing fewer side effects. LimmaTech Biologics is focused on bacterial vaccines in a field shaped by antimicrobial resistance concerns. Lilly framed the acquisitions as aligned with its infectious-disease leadership, including the hiring of FDA’s former vaccine chief Peter Marks. The move follows Lilly’s other major activity across modalities and geographies, with company cash flow supported by obesity and diabetes sales. For vaccine developers, the transaction bundle signals continued valuation appetite from large-cap pharma for platforms and clinical-stage assets that can scale into broader prevention programs.
-
Regulators approve a new targeted BCL2 option for mantle cell lymphoma
The FDA granted accelerated approval to Beqalzi (sonrotoclax), becoming the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma after at least two prior lines of systemic therapy, including a BTK inhibitor. The approval was supported by results from Be One Medicines’ Phase 1/2 BGB-11417-201 trial. Lilly said the trial showed an overall response rate of 52% and complete responses of 16%, with a median time to response of 1.9 months and a median duration of response of 15.8 months at median follow-up of 11.9 months. Continued approval depends on confirmation of clinical benefit in the ongoing Phase 3 CELESTIAL-RRMCL study. The prescribing information includes boxed and significant safety warnings, including tumor lysis syndrome, serious infections, neutropenia, and embryo-fetal toxicity. For oncology teams, the decision adds another targeted option to address limited post-BTK sequencing choices in MCL.
-
Lung and heart disease science meets AI in Lilly-linked gene editing and broader data tools
Lilly’s Phase 1 base-editing results on VERVE-102 are paired with continued momentum in AI-enabled precision approaches for disease biology and clinical decision-making. Separate disclosures from university and industry research teams underscore how computational tools are increasingly used to connect biomarker patterns or tumor genetics to likely treatment responses. In one example, UC San Diego researchers described MutationProjector, an AI framework trained on more than 30,000 solid-tumor cases across 10 cancer types and reported performance that matched or exceeded existing prediction methods in multiple cohorts. In a different direction, work on early detection and risk stratification—such as machine learning for neonatal sepsis prediction—points to the growing role of models in clinical workflow. Taken together, these releases show biotech’s parallel push on genetic medicine execution (including gene editing) and on interpretable model-building for patient selection—both areas that can shorten development cycles if they translate into validated clinical utility.
-
New trials signal faster, smarter fetal risk monitoring with wearable ultrasound
Researchers published results supporting continuous fetal monitoring using a wearable ultrasound patch designed to reduce dependence on highly trained sonographers. The work—led by a team associated with UC San Diego and published in Nature Biotechnology—presents the device as an alternative to intermittent ultrasound assessments, particularly for high-risk pregnancies. Separate reporting describes the same UPatch concept as “autonomous” fetal monitoring, with an emphasis on continuous data capture and risk-focused evaluation rather than single snapshots. The development targets a long-standing clinical gap: access limitations to frequent, skilled ultrasound scans for expectant patients. For biotech and medtech stakeholders, the update highlights an emerging convergence—wearable sensing, signal processing, and clinical validation—where differentiation depends on study endpoints, safety, and performance across gestational ages and patient populations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.